Insider Monkey
GSK (GSK) Scores Win in the Form of Lung Cancer Drug’s Orphan Drug Designation
📊
AI Sentiment
Positive
6/10
- Home
- GSK
as of 12-12-2025 3:55pm EST
$48.85
$0.04
-0.07%
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Chart Type:
Time Range:
| Founded: | 1715 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 95.3B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 4.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.79 | EPS Growth: | 118.57 |
| 52 Week Low/High: | $31.71 - $49.31 | Next Earning Date: | 10-29-2025 |
| Revenue: | $43,237,357,842 | Revenue Growth: | 2.73% |
| Revenue Growth (this year): | 6.56% | Revenue Growth (next year): | 5.13% |
AI-Powered GSK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 64.67%
64.67%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest GSK plc (Each representing two) News
GSK Breaking Stock News: Dive into GSK Ticker-Specific Updates for Smart Investing
The Telegraph
US is best place to invest, says boss of British drugs giant
📉
AI Sentiment
Negative
3/10
GlobeNewswire
$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players
📈
AI Sentiment
Highly Positive
8/10
Zacks
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer
📈
AI Sentiment
Highly Positive
8/10
Zacks
GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Sector Update: Health Care Stocks Rise Premarket Wednesday
📊
AI Sentiment
Positive
6/10
Compare GSK vs Leading Stocks
See how GSK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GSK GSK plc (Each representing two) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.